Protocols for treatment of major depressive disorder (MDD)
    2.
    发明授权
    Protocols for treatment of major depressive disorder (MDD) 有权
    治疗重度抑郁障碍(MDD)的方案

    公开(公告)号:US09572807B2

    公开(公告)日:2017-02-21

    申请号:US14740070

    申请日:2015-06-15

    申请人: NEURALSTEM, INC.

    发明人: Karl K. Johe

    IPC分类号: A61K31/496 A61K31/444

    CPC分类号: A61K31/496 A61K31/444

    摘要: Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.

    摘要翻译: 尽管已知某些苄基哌嗪 - 氨基吡啶或其开链形式在体外试验中刺激神经生长是有效的,但是现在已经令人惊奇地发现,以10mg /天-131mg /天的剂量范围施用这些化合物, 25-35天有效治疗重度抑郁症(MDD),使得只有6名受试者的样本可获得统计学显着的结果。